Go to top of page

Review of medicine name similarity

In 2019–20, the Commission undertook a review of medicine name similarity for two specialised classes of medicines: monoclonal antibodies (with the suffix ‘mab’) and tyrosine kinase inhibitors (with the suffix ‘nib’). This review also considered any other medicines registered in Australia that had the potential to be confused. In December 2019, the Commission published the results of this work, along with a fact sheet containing a supplementary list of specialised medicines ending in the suffix ‘mab’, ‘nib’ or ‘gib’.